Bayer Announces First Colon Cancer Treatment Since 2006 to Receive Health Canada Priority Review

Bayer Inc announced that Health Canada has approved the drug Stivarga, which is used for the treatment of metastatic colorectal cancer based on results from a Phase III study which showed significant improvement in overall survival of patients diagnosed with the disease, compared with approved standard therapies.

As quoted in the press release:

The approval of Stivarga marks the first proven option that increases both overall and progression-free survival in patients with mCRC whose disease has progressed after approved standard therapies,” says Dr. Scot Dowden, medical oncologist at the Tom Baker Cancer Centre in Calgary.  “It is a new reality for mCRC patients who are managing their cancer and living longer – until now there was nothing to offer stage IV patients, they had run out of options.

Click here to read the full Bayer Inc. press release.